Cyclophosphamide
Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD)
Tongji HospitalSmall moleculePhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Tongji Hospital | Phase 1 | CCC |
Lcar-Aio T Cells Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 | CC |
Universal Cd19 Car-Γδt Cell Tongji Hospital | Phase 1 | CC |
ct103a cells Tongji Hospital | Early Phase 1 | C |
Calculus Bovis Sativus Tongji Hospital | N/A | NR |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →